News Channels

29 Jun 2018 Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
29 Jun 2018 uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B
29 Jun 2018 Biogen Exercises Option to Increase Ownership in Samsung Bioepis
29 Jun 2018 Ziopharm Oncology Enrolls First Patient in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO®
29 Jun 2018 CHMP recommends approval of Cablivi(TM) (caplacizumab)
29 Jun 2018 Prestige Biopharma and Alvogen Announce License and Supply Agreement to Commercialize Prestige´s Trastuzumab Biosimilar (Hervelous™) in Central and Eastern Europe
28 Jun 2018 Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
28 Jun 2018 BioAtla Announces First Patient Treated In Phase1/2 BA3021-001 Clinical Trial For CAB-ROR2-ADC Therapeutic
28 Jun 2018 ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa
28 Jun 2018 Arsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Trial of ASN100
28 Jun 2018 Kymab Announces Agreement to Evaluate KY1044, its Novel Antibody Targeting ICOS, and Anti-PD-L1 Immunotherapy for testing in Multiple Solid Tumors
28 Jun 2018 Cocrystal Pharma Commences Enrollment and Initiates Patient Dosing in Phase 2a Study Evaluating CC-31244 for the Treatment of HCV
28 Jun 2018 Retrotope Receives FDA Clearance to Commence RT001 Phase 2/3 Clinical Trial in Patients with Infantile Neuroaxonal Dystrophy (INAD)
28 Jun 2018 Corvus Pharmaceuticals Announces Publication of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity as Monotherapy and in Combination with Anti-PD-1 Therapy in Cancer Immunology, Immunotherapy
28 Jun 2018 Devonian Announces the Signing of a Non-Binding Letter of Intent with Folia Biotech to develop FB-631 in cancer immunotherapy
28 Jun 2018 Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the European Union (EU)
28 Jun 2018 Oral semaglutide shows superior reductions in HbA1c and weight compared to sitagliptin in the long-term safety and efficacy trial, PIONEER 3
28 Jun 2018 MolMed and AbCheck sign a three-year Master Agreement for the development of new CARs targeting novel tumor antigens
28 Jun 2018 Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease
28 Jun 2018 NBE Therapeutics Closes a CHF 20 Million Financing by Novo Holdings A/S

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up